NCT05057819View on ClinicalTrials.gov

Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

August 11, 2022

Study Completion Date

August 11, 2022

Conditions
Dumping SyndromeHypoglycemia, Reactive
Interventions
DRUG

Empagliflozin 25 MG

Treatment naive patients with bariatric bypass surgery will be given oral empagliflozin 25mg once daily for 20 days

DRUG

Placebo

Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days

Trial Locations (1)

3010

Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT05057819 - Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass | Biotech Hunter | Biotech Hunter